Overview

Vytorin in the Treatment of Alopecia Areata

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

Subjects, non pregnant/lactating and over 18years old, with 40% alopecia areata will take vytorin (statin/ezetimibe) for 24 or 52 weeks and be monitored for hair regrowth. The investigators hypothesize that Vytorin medication may have an effect on the inflammatory process of alopecia areata. Inactivating the inflammatory process may help in permitting hair regrowth in those subjects.

Phase:

Phase 1

Details

Lead Sponsor:

University of Miami

Treatments:

Ezetimibe, Simvastatin Drug Combination